Hydrocodone Polistirex
A polymer-bound form of hydrocodone that creates an extended-release formulation by slowing the release of the active opioid in the gastrointestinal tract, providing longer-lasting cough suppression than immediate-release hydrocodone preparations. This formulation is designed for twice-daily dosing in the management of cough. As with all opioid formulations, risks of dependence and respiratory depression require careful patient monitoring.
分子量
299.4000 g/mol
LogP
2.20
TPSA
38.80 Ų
リピンスキーの五則
適合
作用機序
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …
2D構造
Cite this structure
Embed this structure
SMILES
CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4
InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
Molecular Formula
C18H21NO3
HBD / HBA
- / 4
回転可能結合数
1
重原子数
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
A polymer-bound form of hydrocodone that creates an extended-release formulation by slowing the release of the active opioid in the gastrointestinal tract, providing longer-lasting cough suppression than immediate-release hydrocodone preparations. This formulation is designed for twice-daily dosing in the management of cough. As with all opioid formulations, risks of dependence and respiratory depression require careful patient monitoring.
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Yes, Hydrocodone Polistirex is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201470. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5284569. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="hydrocodone-polistirex"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/hydrocodone-polistirex/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/hydrocodone-polistirex/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/hydrocodone-polistirex/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="hydrocodone-polistirex"></drugfyi-drug>